Pulse Biosciences (PLSE) AGM 2026 summary

Opening remarks and agenda

• Meeting opened with introductions of executive leadership, board members, and independent auditors.

• Virtual format enabled global participation; agenda included director elections and auditor ratification.

Board and executive committee updates

• Maria Sainz welcomed to the board, bringing medical technology governance experience.

• Liane Teplitsky introduced as new Chief Operating Officer, noted for positive impact.

• Dr. David Kenigsberg joined full-time as Chief Medical Officer to guide pivotal AFib study.

Financial performance review

• Balance sheet reported strong with $68 million in cash/cash equivalents at Q1 end.

• Increased cash burn focused on strategic initiatives, especially AFib pivotal study.

• Early-stage revenue recorded from commercial thyroid technology program.

• $13.3 million insider investment announced in May via ATM vehicle.

• Upcoming warrant redemption to raise approximately $2.1 million.